为何尼日利亚必须加强其本土制药生产能力。
Why Nigeria Must Strengthen its Local Pharmaceutical Manufacturing Capacity.
作者信息
Okereke Melody, Adekunbi Adebowale, Ghazali Yusuf
机构信息
Faculty of Pharmaceutical Sciences, University of Ilorin, Kwara State, Nigeria.
Consultant, Regulatory Information Management and Systems.
出版信息
Innov Pharm. 2021 Sep 22;12(4). doi: 10.24926/iip.v12i4.4208. eCollection 2021.
Abstract
With over 115 registered pharmaceutical manufacturers, Nigeria still depends on other countries for the supply of active pharmaceutical ingredients and excipients. Significant attention has not been paid to the local production of raw materials, pharmaceutical dosage formulations, or processing equipment, which has resulted in a decline in the country's pharmaceutical manufacturing capacity. Owing to the overall importance of the pharmaceutical industry, it is, therefore, essential to pay close attention to developmental issues affecting this sector. In this commentary, we explore why Nigeria must boost its local pharmaceutical manufacturing capacity.
摘要
尼日利亚有超过115家注册制药商，但该国在活性药物成分和辅料供应方面仍依赖其他国家。对原材料、药物剂型或加工设备的本地生产未给予足够重视，这导致该国制药产能下降。鉴于制药行业的整体重要性，因此必须密切关注影响该行业的发展问题。在这篇评论中，我们探讨了尼日利亚为何必须提高其本地制药产能。
相似文献
1
Why Nigeria Must Strengthen its Local Pharmaceutical Manufacturing Capacity.为何尼日利亚必须加强其本土制药生产能力。
Innov Pharm. 2021 Sep 22;12(4). doi: 10.24926/iip.v12i4.4208. eCollection 2021.
2
Implications of national tax policy on local pharmaceutical production in a southwestern state nigeria - qualitative research for the intersection of national pharmaceutical policy on health systems development.尼日利亚西南部国家税收政策对当地制药生产的影响——国家制药政策对卫生系统发展交叉点的定性研究。
BMC Health Serv Res. 2022 Feb 28;22(1):264. doi: 10.1186/s12913-022-07579-1.
3
The State of Pharmaceutical Manufacturing in the Democratic Republic of Congo: The Journey so Far.刚果民主共和国的制药制造业现状：迄今为止的历程。
Innov Pharm. 2022 Apr 2;13(1). doi: 10.24926/iip.v13i1.4466. eCollection 2022.
4
Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.巴基斯坦当地制药行业实施和遵守国际公认质量标准的体制障碍和促进因素：一项定性研究。
Health Policy Plan. 2019 Jul 1;34(6):440-449. doi: 10.1093/heapol/czz054.
5
Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.设备与分析公司面临持续挑战。2014年5月20 - 21日 连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):821-31. doi: 10.1002/jps.24282. Epub 2014 Dec 1.
6
Achieving continuous manufacturing for final dosage formation: challenges and how to meet them. May 20-21, 2014 Continuous Manufacturing Symposium.实现最终剂型的连续制造：挑战与应对方法。2014年5月20 - 21日连续制造研讨会
J Pharm Sci. 2015 Mar;104(3):792-802. doi: 10.1002/jps.24247. Epub 2014 Dec 12.
7
Vendor qualification for pharmaceutical excipients--GMP requirements and approach.药用辅料的供应商资质认定——GMP要求及方法
Pharmazie. 2010 Nov;65(11):783-90.
8
Importance and globalization status of good manufacturing practice (GMP) requirements for pharmaceutical excipients.药用辅料良好生产规范（GMP）要求的重要性及其全球化地位。
Saudi Pharm J. 2015 Jan;23(1):9-13. doi: 10.1016/j.jsps.2013.06.003. Epub 2013 Jun 26.
9
[An analysis of the pharmaceuticals market in Vietnam].[越南药品市场分析]
Sante. 2001 Jul-Sep;11(3):155-60.
10
Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges.巴西能否在全球结核病药物生产中发挥更重要的作用？对当前能力和挑战的评估。
BMC Public Health. 2013 Mar 27;13:279. doi: 10.1186/1471-2458-13-279.
引用本文的文献
1
A narrative review on problems in product quality, regulatory system constraints, and the concept of quality by design as a solution for quality assurance of African medicines.一篇关于产品质量问题、监管制度限制以及设计质量概念作为非洲药品质量保证解决方案的叙述性综述。
Front Med (Lausanne). 2024 Oct 3;11:1472495. doi: 10.3389/fmed.2024.1472495. eCollection 2024.
2
Promoting local production and active pharmaceutical ingredient (API) industry in low and middle income countries (LMICs): impact on medicines access and policy.促进低收入和中等收入国家（LMICs）的本地生产和活性药物成分（API）产业：对药品可及性和政策的影响。
J Pharm Policy Pract. 2024 Mar 4;17(1):2323683. doi: 10.1080/20523211.2024.2323683. eCollection 2024.
3
The Urgent Need to Intensify Vaccine Development and Manufacturing in Africa: Lessons from Emerging Pandemics.非洲加强疫苗研发和生产的迫切需求：新发大流行病的教训
Innov Pharm. 2022 Dec 26;13(4). doi: 10.24926/iip.v13i4.5049. eCollection 2022.
4
An Evaluation of Local Pharmaceutical Manufacturing in Zimbabwe: How Prepared is Zimbabwe to Produce COVID-19 Vaccines?津巴布韦本土制药业评估：津巴布韦生产新冠疫苗的准备情况如何？
Innov Pharm. 2022 Apr 2;13(1). doi: 10.24926/iip.v13i1.4656. eCollection 2022.
5
The State of Pharmaceutical Manufacturing in the Democratic Republic of Congo: The Journey so Far.刚果民主共和国的制药制造业现状：迄今为止的历程。
Innov Pharm. 2022 Apr 2;13(1). doi: 10.24926/iip.v13i1.4466. eCollection 2022.
6
Increasing challenges of malaria control in sub-Saharan Africa: Priorities for public health research and policymakers.撒哈拉以南非洲疟疾控制面临的挑战日益增加：公共卫生研究与政策制定者的优先事项
Ann Med Surg (Lond). 2022 Aug 18;81:104366. doi: 10.1016/j.amsu.2022.104366. eCollection 2022 Sep.
7
The need for a functional pharmaceutical industry in Sierra Leone: lessons from the COVID-19 pandemic.塞拉利昂对功能性制药行业的需求：来自新冠疫情的教训
J Pharm Policy Pract. 2022 Jul 27;15(1):46. doi: 10.1186/s40545-022-00444-w.
本文引用的文献
1
COVID-19 in Nigeria: Is the pharmaceutical sector spared?尼日利亚的新冠疫情：制药行业幸免了吗？
Public Health Pract (Oxf). 2020 Nov;1:100044. doi: 10.1016/j.puhip.2020.100044. Epub 2020 Dec 22.
Zotero 插件